Last reviewed · How we verify
Multiple Ascending Dose SC — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Multiple Ascending Dose SC (Multiple Ascending Dose SC) — Bristol-Myers Squibb.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Multiple Ascending Dose SC TARGET | Multiple Ascending Dose SC | Bristol-Myers Squibb | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Multiple Ascending Dose SC CI watch — RSS
- Multiple Ascending Dose SC CI watch — Atom
- Multiple Ascending Dose SC CI watch — JSON
- Multiple Ascending Dose SC alone — RSS
Cite this brief
Drug Landscape (2026). Multiple Ascending Dose SC — Competitive Intelligence Brief. https://druglandscape.com/ci/multiple-ascending-dose-sc. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab